Xencor Inc. (NASDAQ:XNCR) is one of the best high short interest stocks with biggest upside potential. On January 6, Bank of America raised its price target for Xencor to $20 from $17 while maintaining a Neutral rating. This sentiment was announced by the firm as part of its broader update to its US Biopharmaceuticals coverage.
The firm suggested that the biotech sector is experiencing a resurgence driven by several stabilizing factors, including a reward for positive data catalysts, increased large-cap M&A and licensing activity, better access to capital, and a limited impact from drug price regulations. While BofA noted that fundamental pieces are falling into place for the industry, the firm remains cautious regarding the long-term sustainability of this recovery.
Additionally, earlier on December 17, Barclays also raised its price target for Xencor Inc. from $23 to $26 and maintained an Overweight rating. This decision followed an adjustment of valuations across the biotech sector as part of its 2026 outlook.
Xencor Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
